title: Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
abstract: OBJECTIVE
  To clarify the relationship between age and pathologic Gleason score and their effect on prostate-specific antigen recurrence (PSAR).
  
  
  METHODS
  The data from a cohort of 2911 men who had undergone radical prostatectomy from 1988 to 2006 were retrieved from the Duke Prostate Center database. Patient age was divided into 3 groups: <60, 60-64, and >or=65 years. The pathologic Gleason score was divided into 5 groups: <or=5, 6, 3 + 4, 4 + 3, and >7. PSAR was defined as the prostate-specific antigen level increasing to >0.2 ng/mL >30 days after radical prostatectomy. The associations between age and pathologic Gleason score on PSAR and the time to PSAR were analyzed using parametric, nonparametric, Kaplan-Meier, and Cox regression techniques.
  
  
  RESULTS
  Patient age and interval to PSAR had no significant association (P > .05). Kaplan-Meier analysis demonstrated a significant difference in PSAR among age groups. The pathologic Gleason scores of 3 + 3, 3 + 4, 4 + 3, and >7 were significant in determining the incidence of PSAR. Age was not significant for PSAR in patients with a pathologic Gleason score of <or=7. In patients with a pathologic Gleason score of >7, a statistically significant difference was observed among the age groups. Men <60 years old with a pathologic Gleason score >7 had a lower incidence of PSAR than did older men with a similar pathologic Gleason score. A pathologic Gleason score of >or=6 was significant in predicting PSAR.
  
  
  CONCLUSIONS
  Age alone was an independent factor in predicting PSAR, but not in predicting the interval to PSAR. The pathologic Gleason score remained a predictor of PSAR, and patient age should be considered in patients with a pathologic Gleason score >7.
authors.affiliation: Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: David D
authors.initials: DD
authors.lastname: Xu
authors.forename: Sandy D
authors.initials: SD
authors.lastname: Sun
authors.forename: Flint
authors.initials: F
authors.lastname: Wang
authors.forename: Leon
authors.initials: L
authors.lastname: Sun
authors.forename: Danielle
authors.initials: D
authors.lastname: Stackhouse
authors.forename: Thomas
authors.initials: T
authors.lastname: Polascik
authors.forename: David M
authors.initials: DM
authors.lastname: Albala
authors.forename: Judd W
authors.initials: JW
authors.lastname: Moul
authors.forename: Arthur
authors.initials: A
authors.lastname: Caire
authors.forename: Cary N
authors.initials: CN
authors.lastname: Robertson
mesh_terms: D000367:Age Factors; D000368:Aged; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000453:epidemiology; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen